CVRx Logo_R_RGB_black.png
CVRx® Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Barostim™ for the Treatment of Heart Failure Symptoms
June 10, 2021 11:19 ET | CVRx, Inc.
MINNEAPOLIS, June 10, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced the completion of the...
Fierce Medtech Names CVRx as One of its “Fierce 15” Companies
March 15, 2021 10:00 ET | CVRx, Inc.
MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announces it has been selected...
CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing
January 05, 2021 10:55 ET | CVRx, Inc.
MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that it is expanding...
CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status
December 03, 2020 11:54 ET | CVRx, Inc.
MINNEAPOLIS, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that the Centers for...
CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts
November 18, 2020 14:56 ET | CVRx, Inc.
MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) -- CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s...